anti-bcma bispecific antibody for myeloma relapse after car t cells
Published 1 year ago • 231 plays • Length 44:36Download video MP4
Download video MP3
Similar videos
-
2:45
emerging treatments for myeloma: quadruplets, bispecific antibodies & car t-cells
-
3:17
anti-bcma car t-cells for mm: durable clinical responses with ide-cel (formerly bb2121)
-
10:18
ide-cel; bb2121, a bcma-targeted car t-cell therapy, in patients with rrmm: initial karmma results
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
1:53
infections following anti-bcma bispecific antibodies for multiple myeloma
-
7:06
efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm
-
3:22
anti-bcma car t-cell therapy in myeloma: updates from ash 2020
-
1:15
how bcma targeting bispecific antibodies may impact the subsequent use of car-t therapy in myeloma
-
11:40
immunotherapy of myeloma: bcma/slamf7 car t-cells & bites
-
4:35
bispecific antibodies vs car t-cells for r/r multiple myeloma
-
1:45
anti-bcma car t-cell therapy for multiple myeloma: latest studies
-
2:22
combining car-ts & bispecific antibodies
-
3:44
phase i study of teclistamab, a humanized bcma x cd3 bispecific antibody, in relapsed/refractory mm
-
1:23
targeting bcma with bispecific antibodies in r/r myeloma
-
5:12
clinical activity seen with anti-bcma car t-cell therapy for heavily pre-treated multiple myeloma
-
4:25
efficacy and safety of p-bcma-101 car-t cells in patients with relapsed/refractory multiple myeloma
-
8:13
bcma-targeted bites for multiple myeloma
-
5:00
meta-analysis: anti-bcma car-t in r/r multiple myeloma
-
57:20
know your myeloma immunotherapy: bispecific antibodies with dr. cesar rodriguez